Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

NEWCARBOVAX

Financiado

Cerrado

New generation of carbohydrate based vaccines via rational understanding of thei...

New generation of carbohydrate based vaccines via rational understanding of their immunological mechanism Glycoconjugate vaccines have provided enormous health benefits globally, but they have been less successful in some populations at high risk for developing disease. They are composed by a sugar antigen covalently linked to a carri... ver más

31/12/2019

UMIL

244K€

Presupuesto del proyecto: 244K€

Líder del proyecto

UNIVERSITA DEGLI STUDI DI MILANO No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 4 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-12-31

MSCA-IF-2014-GF: Marie Skłodowska-Curie Individual F...

I+D

Cerrada hace 10 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

4 Participantes

UMIL

244.27K€ | Lider

GSK Vaccines Srl

N.D. | Participante

PRESIDENT AND FELLOWS OF HAR...

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

GLYCOVAX A training network for the rational design of the next gener... 4M€ Cerrado

DynOMIS Dynamic Origins of MHC class I Selector function 195K€ Cerrado

PhosPepPres Improving Peptide-Based Anti-Cancer Vaccines with Phosphatas... 150K€ Cerrado

KineTic New Reagents for Quantifying the Routing and Kinetics of T c... 2M€ Cerrado

SAF2014-58052-R DISEÑO DE VACUNAS RECOMBINANTES POLIEPITOPICAS PARA GENERAR... 145K€ Cerrado

CUT'HIVAC Cutaneous and Mucosal HIV Vaccination 15M€ Cerrado

Duración del proyecto: 55 meses Fecha Inicio: 2015-05-18
Fecha Fin: 2019-12-31

Líder del proyecto

UNIVERSITA DEGLI STUDI DI MILANO No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 244K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Glycoconjugate vaccines have provided enormous health benefits globally, but they have been less successful in some populations at high risk for developing disease. They are composed by a sugar antigen covalently linked to a carrier protein. The traditional hypothesis of immune activation by glycoconjugate vaccines suggests that only peptides generated from glycoconjugate processing can be presented to and recognized by T cells, and this contribution is crucial for their immunogenicity. In most cases, conjugation processes have been set-up empirically. Recently, new findings offer a rational explanation for how conjugates work and may render vaccine development a more straightforward process. In contrast with the classical mechanism, this new model suggests that carbohydrate presentation to the T cell by antigen-presenting cell may strongly enhance antibody response. The key strategy is to conjugate the carbohydrate to peptides which anchor the conjugate via MHC class II and allow the sugar epitope to be presented via the T cell receptor. Application of this principle resulted in a GBSIII vaccine strongly protective in a mouse model and 50–100 times more immunogenic than a traditional vaccine composed by random linking of the sugar on a protein carrier. Although the principle has been demonstrated much remains to be done to generally apply the concept to generate vaccines for clinical use. In the proposed study, we will extend the approach by analysing different variables (peptide carrier, glycan chain length, conjugation chemistry and microbial antigen), with the aim of using the increased understanding of basic immunological mechanisms to develop a new translational platform for optimized and cost-effective carbohydrate-based vaccines. Innovative strategies of conjugation chemistry will be also evaluated to generate new therapeutics with chemical properties designed in light of specific information on antigen presentation.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores